{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:07:43Z","timestamp":1781770063865,"version":"3.54.5"},"reference-count":76,"publisher":"Becaris Publishing Limited","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>\n            <jats:bold>Aim<\/jats:bold>\n            To conduct a systematic literature review of high-risk resectable cutaneous melanoma adjuvant therapeutics and compare safety and efficacy.\n            <jats:bold>Methods:<\/jats:bold>\n            The systematic literature review included randomized controlled trials investigating: dabrafenib plus trametinib (DAB\u00a0+\u00a0TRAM), nivolumab, pembrolizumab, ipilimumab, vemurafenib, chemotherapy and interferons. Outcomes included overall survival (OS), relapse-free survival, distant metastasis-free survival and safety. All outcomes were synthesized using Bayesian network meta-analysis.\n            <jats:bold>Results:<\/jats:bold>\n            Across relapse-free survival, distant metastasis-free survival and OS, DAB\u00a0+\u00a0TRAM had the lowest estimated hazards of respective events relative to all other treatments (exception relative to nivolumab in OS). Differences were significant relative to placebo, chemotherapy, interferons and ipilimumab.\n            <jats:bold>Conclusion:<\/jats:bold>\n            DAB\u00a0+\u00a0TRAM has improved efficacy over historical treatment options (ipilimumab, interferons and chemotherapy) and comparable efficacy with other targeted and immune checkpoint inhibitors.\n          <\/jats:p>","DOI":"10.2217\/cer-2019-0061","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T14:57:57Z","timestamp":1574953077000},"page":"1349-1363","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma"],"prefix":"10.57264","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-0547","authenticated-orcid":false,"given":"Rohini","family":"Sharma","sequence":"first","affiliation":[{"name":"Precision Xtract, Vancouver, British Columbia, V6H 3Y4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Koruth","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[{"name":"Precision Xtract, Vancouver, British Columbia, V6H 3Y4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Druyts","sequence":"additional","affiliation":[{"name":"Precision Xtract, Vancouver, British Columbia, V6H 3Y4, Canada"},{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA"},{"name":"Moffitt Comprehensive Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Moffitt Comprehensive Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_4_2_2","unstructured":"American Cancer Society. Cancer facts and figures (2008). www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2008\/cancer-facts-and-figures-2008.pdf"},{"key":"e_1_3_4_3_2","unstructured":"National Cancer Institute. Cancer stat facts: melanoma of the skin (2018). https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html"},{"key":"e_1_3_4_4_2","unstructured":"National Cancer Institute. Cancer stat facts: melanoma of the skin (2019). https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html"},{"key":"e_1_3_4_5_2","unstructured":"American Cancer Society. Cancer facts & figures (2017). www.cancer.org\/acs\/groups\/content\/@editorial\/documents\/document\/acspc-048738.pdf"},{"issue":"5","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay J","year":"2015","unstructured":"Ferlay J , Soerjomataram I , Dikshit R Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"issue":"36","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch CM","year":"2009","unstructured":"Balch CM , Gershenwald JE , Soong SJ Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199\u20136206 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clon.2011.12.002","article-title":"Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline","volume":"24","author":"Petrella T","year":"2012","unstructured":"Petrella T , Verma S , Spithoff K , Quirt I , McCready D . Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin. Oncol. 24(6), 413\u2013423 (2012).","journal-title":"Clin. Oncol."},{"issue":"7","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","article-title":"Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma","volume":"106","author":"Verma S","year":"2006","unstructured":"Verma S , Quirt I , McCready D , Bak K , Charette M , Iscoe N . Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106(7), 1431\u20131442 (2006).","journal-title":"Cancer"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto PA","year":"2012","unstructured":"Ascierto PA , Kirkwood JM , Grob JJ The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85\u201385 (2012).","journal-title":"J. Transl. Med."},{"issue":"32","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1038\/onc.2011.160","article-title":"Raf kinases in cancer-roles and therapeutic opportunities","volume":"30","author":"Maurer G","year":"2011","unstructured":"Maurer G , Tarkowski B , Baccarini M . Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 30(32), 3477\u20133488 (2011).","journal-title":"Oncogene"},{"issue":"7","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/carcin\/bgp337","article-title":"Targets of Raf in tumorigenesis","volume":"31","author":"Niault TS","year":"2010","unstructured":"Niault TS , Baccarini M . Targets of Raf in tumorigenesis. Carcinogenesis 31(7), 1165\u20131174 (2010).","journal-title":"Carcinogenesis"},{"issue":"15","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","article-title":"BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy","volume":"50","author":"Barbour AP","year":"2014","unstructured":"Barbour AP , Tang YH , Armour N BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy . Eur. J. Cancer 50(15), 2668\u20132676 (2014).","journal-title":"Eur. J. Cancer"},{"issue":"6892","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies H","year":"2002","unstructured":"Davies H , Bignell GR , Cox C Mutations of the BRAF gene in human cancer. Nature 417(6892), 949\u2013954 (2002).","journal-title":"Nature"},{"key":"e_1_3_4_15_2","unstructured":"European Medicines Agency. An overview of Tafinlar and why it is authorised in the EU (2018). www.ema.europa.eu\/medicines\/human\/EPAR\/Tafinlar"},{"key":"e_1_3_4_16_2","unstructured":"European Medicines Agency. An overview of Mekinist and why it is authorised in the EU (2018). www.ema.europa.eu\/medicines\/human\/EPAR\/mekinist"},{"key":"e_1_3_4_17_2","unstructured":"US FDA. Opdivo (nivolumab) prescribing information (2018). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125554s055lbl.pdf"},{"key":"e_1_3_4_18_2","unstructured":"US FDA. FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600E or V600K mutations (2018). www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm606165.htm"},{"key":"e_1_3_4_19_2","unstructured":"US FDA. Keytruda (pembrolizumab) prescribing information (2019). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125514s040lbl.pdf"},{"key":"e_1_3_4_20_2","unstructured":"Genentech. Zelboraf (vemurafenib) prescribing information (2019). www.gene.com\/download\/pdf\/zelboraf_prescribing.pdf"},{"issue":"5","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias S","year":"2013","unstructured":"Dias S , Sutton AJ , Ades AE , Welton NJ . Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Making 33(5), 607\u2013617 (2013).","journal-title":"Med. Decis. Making"},{"issue":"4","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen JP","year":"2011","unstructured":"Jansen JP , Fleurence R , Devine B Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4), 417\u2013428 (2011).","journal-title":"Value Health"},{"issue":"12","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills EJ","year":"2012","unstructured":"Mills EJ , Ioannidis JP , Thorlund K , Schunemann HJ , Puhan MA , Guyatt GH . How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 308(12), 1246\u20131253 (2012).","journal-title":"JAMA"},{"issue":"20","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu G","year":"2004","unstructured":"Lu G , Ades AE . Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105\u20133124 (2004).","journal-title":"Stat. Med."},{"key":"e_1_3_4_25_2","unstructured":"University of York. Systematic Reviews (2009). www.york.ac.uk\/crd\/guidance"},{"key":"e_1_3_4_26_2","unstructured":"Cochrane Training. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (2019). http:\/\/handbook.cochrane.org"},{"issue":"19","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont AMM","year":"2018","unstructured":"Eggermont AMM , Blank CU , Mandala M Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378(19), 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_4_28_2","article-title":"Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600\u2013mutant stage III melanoma","volume":"29","author":"Long GV","year":"2018","unstructured":"Long GV , Hauschild A , Santinami M Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600\u2013mutant stage III melanoma. Annals of Oncology 29(Suppl. 8), mdy424-053 (2018).","journal-title":"Annals of Oncology"},{"issue":"15","key":"e_1_3_4_29_2","article-title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III\/IV melanoma: updated results from a Phase III trial (CheckMate 238)","volume":"36","author":"Weber J","year":"2018","unstructured":"Weber J , Mandal\u00e0 M , Del Vecchio M Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III\/IV melanoma: updated results from a Phase III trial (CheckMate 238). J. Clin. Oncol. 36(Suppl. 15), Abstract 9502 (2018).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_30_2","unstructured":"Healthcare Improvement Scotland \u2013 SIGN. Search filters (2018). www.sign.ac.uk\/search-filters.html"},{"issue":"10","key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher D","year":"2009","unstructured":"Moher D , Liberati A , Tetzlaff J , Altman DG , Group P . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006\u20131012 (2009).","journal-title":"J. Clin. Epidemiol."},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"d592598","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP , Altman DG , Gotzsche PC The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d592598 (2011).","journal-title":"BMJ"},{"issue":"4","key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1018598421607","article-title":"The direct use of likelihood for significance testing","volume":"7","author":"Dempster AP","year":"1997","unstructured":"Dempster AP . The direct use of likelihood for significance testing. Stat. Comput. 7(4), 247\u2013252 (1997).","journal-title":"Stat. Comput."},{"issue":"5","key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence Synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias S","year":"2013","unstructured":"Dias S , Welton NJ , Sutton AJ , Caldwell DM , Lu G , Ades AE . Evidence Synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med. Decis. Making 33(5), 641\u2013656 (2013).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_4_35_2","first-page":"92","article-title":"Establishing the relationship between relapse-free survival and overall survival in adjuvant high-risk radically resected cutaneous melanoma","volume":"32","author":"Koruth R","year":"2019","unstructured":"Koruth R , Sharma R , Kanters S , Druyts E , Kirkwood J . Establishing the relationship between relapse-free survival and overall survival in adjuvant high-risk radically resected cutaneous melanoma. Pigment Cell Melanoma Res. 32, 92\u2013172 (2019).","journal-title":"Pigment Cell Melanoma Res."},{"issue":"1","key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-free survival as a surrogate for overall survival in the evaluation of stage II\u2013III melanoma adjuvant therapy","volume":"110","author":"Suciu S","year":"2018","unstructured":"Suciu S , Eggermont AMM , Lorigan P Relapse-free survival as a surrogate for overall survival in the evaluation of stage II\u2013III melanoma adjuvant therapy. J. Natl Cancer Inst. 110(1), 87\u201396 (2018).","journal-title":"J. Natl Cancer Inst."},{"issue":"8","key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.2016.70.2951","article-title":"Phase III randomized study of 4 weeks of high-dose interferon-alpha-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: A trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)","volume":"35","author":"Agarwala SS","year":"2017","unstructured":"Agarwala SS , Lee SJ , Yip W Phase III randomized study of 4 weeks of high-dose interferon-alpha-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: A trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J. Clin. Oncol. 35(8), 885\u2013892 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_4_38_2","first-page":"78","article-title":"Treatment with neoadjuvant+adjuvant dabrafenib and trametinib (D+T) is associated with improved relapse-free survival (RFS) versus standard of care (SOC) therapy in patients with high-risk resectable BRAF-mutant melanoma","volume":"30","author":"Amaria RN","year":"2016","unstructured":"Amaria RN , Prieto P , Tetzlaff M Treatment with neoadjuvant+adjuvant dabrafenib and trametinib (D+T) is associated with improved relapse-free survival (RFS) versus standard of care (SOC) therapy in patients with high-risk resectable BRAF-mutant melanoma. Pigment Cell & Melanoma Research. 30(1), 78 (2016).","journal-title":"Pigment Cell & Melanoma Research"},{"issue":"9","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1054\/bjoc.2000.1623","article-title":"Adjuvant interferon alpha 2b in high risk melanoma \u2013 the Scottish study","volume":"84","author":"Cameron DA","year":"2001","unstructured":"Cameron DA , Cornbleet MC , Mackie RM Adjuvant interferon alpha 2b in high risk melanoma \u2013 the Scottish study. Br. J. Cancer 84(9), 1146\u20131149 (2001).","journal-title":"Br. J. Cancer"},{"issue":"15","key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/jco.2011.29.15_suppl.8506","article-title":"Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: a randomized Phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]","volume":"29","author":"Chiarion-Sileni V","year":"2011","unstructured":"Chiarion-Sileni V , Guida M , Romanini A , Ridolfi R , Mandala M . Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: a randomized Phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. Journal of Clinical Oncology. 29(Suppl. 15), 8506 (2011).","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.1995.13.11.2776","article-title":"Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma","volume":"13","author":"Creagan ET","year":"1995","unstructured":"Creagan ET , Dalton RJ , Ahmann DL Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J. Clin. Oncol. 13(11), 2776\u20132783 (1995).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, Phase III trial","volume":"16","author":"Eggermont AM","year":"2015","unstructured":"Eggermont AM , Chiarion-Sileni V , Grob JJ Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, Phase III trial. Lancet Oncol. 16(5), 522\u2013530 (2015).","journal-title":"Lancet Oncol."},{"issue":"9492","key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont AM","year":"2005","unstructured":"Eggermont AM , Suciu S , Mackie R Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366(9492), 1189\u20131196 (2005).","journal-title":"Lancet"},{"issue":"9633","key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial","volume":"372","author":"Eggermont AM","year":"2008","unstructured":"Eggermont AM , Suciu S , Santinami M Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet 372(9633), 117\u2013126 (2008).","journal-title":"Lancet"},{"issue":"8","key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/annonc\/mdw225","article-title":"Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized Phase III DeCOG trial","volume":"27","author":"Eigentler TK","year":"2016","unstructured":"Eigentler TK , Gutzmer R , Hauschild A Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized Phase III DeCOG trial. Ann. Oncol. 27(8), 1625\u20131632 (2016).","journal-title":"Ann. Oncol."},{"issue":"5","key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/CMR.0b013e32830e3936","article-title":"Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group","volume":"18","author":"Eigentler TK","year":"2008","unstructured":"Eigentler TK , Radny P , Hauschild A Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res. 18(5), 353\u2013358 (2008).","journal-title":"Melanoma Res."},{"issue":"9120","key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases","volume":"351","author":"Grob JJ","year":"1998","unstructured":"Grob JJ , Dreno B , De La Salmoniere P Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351(9120), 1905\u20131910 (1998).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1200\/JCO.2004.03.185","article-title":"Adjuvant interferon in high-risk melanoma: The AIM HIGH study \u2013 United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma","volume":"22","author":"Hancock BW","year":"2004","unstructured":"Hancock BW , Wheatley K , Harris S Adjuvant interferon in high-risk melanoma: The AIM HIGH study \u2013 United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22(1), 53\u201361 (2004).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1470-2045(10)70288-6","article-title":"Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised Phase III trial","volume":"12","author":"Hansson J","year":"2011","unstructured":"Hansson J , Aamdal S , Bastholt L Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised Phase III trial. Lancet Oncol. 12(2), 144\u2013152 (2011).","journal-title":"Lancet Oncol."},{"issue":"1","key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00000421-198502000-00045","article-title":"Adjuvant chemotherapy of malignant melanoma. A pilot study","volume":"8","author":"Hansson J","year":"1985","unstructured":"Hansson J , Ringborg U , Lagerlof B , Strander H . Adjuvant chemotherapy of malignant melanoma. A pilot study. Am. J. Clin. Oncol. 8(1), 47\u201350 (1985).","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2009.23.1704","article-title":"Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized Phase III DeCOG trial","volume":"28","author":"Hauschild A","year":"2010","unstructured":"Hauschild A , Weichenthal M , Rass K Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized Phase III DeCOG trial. J. Clin. Oncol. 28(5), 841\u2013846 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"e_1_3_4_52_2","first-page":"1831","article-title":"Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma","volume":"29","author":"Karakousis C","year":"1993","unstructured":"Karakousis C , Blumenson L . Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. Eur. J. Cancer 1990 29A(13), 1831\u20131835 (1993).","journal-title":"Eur. J. Cancer 1990"},{"issue":"1","key":"e_1_3_4_53_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jso.2930360115","article-title":"Adjuvant chemotherapy in high-risk malignant melanoma","volume":"36","author":"Karakousis CP","year":"1987","unstructured":"Karakousis CP , Emrich LJ . Adjuvant chemotherapy in high-risk malignant melanoma. J. Surg. Oncol. 36(1), 64\u201367 (1987).","journal-title":"J. Surg. Oncol."},{"issue":"5","key":"e_1_3_4_54_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0748-7983(95)97305-2","article-title":"Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma","volume":"21","author":"Kerin MJ","year":"1995","unstructured":"Kerin MJ , Gillen P , Monson JRT , Wilkie J , Keane FBV , Tanner WA . Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma. Eur. J. Surg. Oncol. 21(5), 548\u2013550 (1995).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"e_1_3_4_55_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CMR.0b013e328314b84a","article-title":"A randomized Phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence","volume":"19","author":"Kim KB","year":"2009","unstructured":"Kim KB , Legha SS , Gonzalez R A randomized Phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 19(1), 42\u201349 (2009).","journal-title":"Melanoma Res."},{"issue":"5","key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.10775","article-title":"Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690","volume":"95","author":"Kirkwood JM","year":"2002","unstructured":"Kirkwood JM , Richards T , Zarour HM Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95(5), 1101\u20131112 (2002).","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_4_57_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood JM","year":"1996","unstructured":"Kirkwood JM , Strawderman MH , Ernstoff MS , Smith TJ , Borden EC , Blum RH . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7\u201317 (1996).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"e_1_3_4_58_2","first-page":"390","article-title":"Final results of the EORTC 18871\/DKG 80-1 randomised Phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis","volume":"40","author":"Kleeberg UR","year":"2004","unstructured":"Kleeberg UR , Suciu S , Brocker EB Final results of the EORTC 18871\/DKG 80-1 randomised Phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur. J. Cancer 40(3), 390\u2013402 (2004).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"e_1_3_4_59_2","first-page":"S81","article-title":"An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A Phase III adjuvant study. EORTC protocol 18761","volume":"24","author":"Lejeune FJ","year":"1988","unstructured":"Lejeune FJ , Macher E , Kleeberg U An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A Phase III adjuvant study. EORTC protocol 18761. Eur. J. Cancer Clin. Oncol. 24(Suppl. 2), S81\u2013S90 (1988).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"5","key":"e_1_3_4_60_2","first-page":"v605","article-title":"BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients with completely resected BRAFV600+ melanoma at high risk for recurrence","volume":"28","author":"Lewis K","year":"2017","unstructured":"Lewis K , Maio M , Demidov L BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients with completely resected BRAFV600+ melanoma at high risk for recurrence. An. Onco.. 28(Suppl. 5), v605\u2013v649 (2017).","journal-title":"An. Onco."},{"issue":"19","key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long GV","year":"2017","unstructured":"Long GV , Hauschild A , Santinami M Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377(19), 1813\u20131823 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ejca.2011.03.019","article-title":"A randomised Phase II trial of 1 month versus 1 year of adjuvant high-dose interferon [alpha]-2b in high-risk acral melanoma patients","volume":"47","author":"Mao L","year":"2011","unstructured":"Mao L , Si L , Chi Z A randomised Phase II trial of 1 month versus 1 year of adjuvant high-dose interferon [alpha]-2b in high-risk acral melanoma patients. Eur. J. Cancer 47(10), 1498\u20131503 (2011).","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"e_1_3_4_63_2","doi-asserted-by":"crossref","first-page":"e21073","DOI":"10.1200\/JCO.2016.34.15_suppl.e21073","article-title":"Imatinib versus interferon as adjuvant therapy in a Phase II study in patients with highrisk c-kit mutated melanoma","volume":"34","author":"Mao L","year":"2016","unstructured":"Mao L , Si L , Kong Y , Wang X , Lian B , Chi Z . Imatinib versus interferon as adjuvant therapy in a Phase II study in patients with highrisk c-kit mutated melanoma. Journal of Clinical Oncology. 34(Suppl. 15), e21073 (2016).","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"e_1_3_4_64_2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jnci\/85.13.1080","article-title":"Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma","volume":"85","author":"Meisenberg BR","year":"1993","unstructured":"Meisenberg BR , Ross M , Vredenburgh JJ Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. J. Natl Cancer Inst. 85(13), 1080\u20131085 (1993).","journal-title":"J. Natl Cancer Inst."},{"issue":"34","key":"e_1_3_4_65_2","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2014.59.6932","article-title":"Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized Phase III dermatologic cooperative oncology group trial","volume":"33","author":"Mohr P","year":"2015","unstructured":"Mohr P , Hauschild A , Trefzer U Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized Phase III dermatologic cooperative oncology group trial. J. Clin. Oncol. 33(34), 4077\u20134084 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"e_1_3_4_66_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2013.49.8717","article-title":"Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence","volume":"32","author":"Payne MJ","year":"2014","unstructured":"Payne MJ , Argyropoulou K , Lorigan P Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J. Clin. Oncol. 32(3), 185\u2013190 (2014).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"e_1_3_4_67_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/JCO.2008.16.3121","article-title":"Randomized Phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma","volume":"27","author":"Pectasides D","year":"2009","unstructured":"Pectasides D , Dafni U , Bafaloukos D Randomized Phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J. Clin. Oncol. 27(6), 939\u2013944 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_4_68_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group","volume":"16","author":"Pehamberger H","year":"1998","unstructured":"Pehamberger H , Soyer HP , Steiner A Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol. 16(4), 1425\u20131429 (1998).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_4_69_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/02841860600630954","article-title":"Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomised multicentre trial","volume":"45","author":"Stadler R","year":"2006","unstructured":"Stadler R , Luger T , Bieber T Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomised multicentre trial. Acta Oncol. 45(4), 389\u2013399 (2006).","journal-title":"Acta Oncol."},{"issue":"15","key":"e_1_3_4_70_2","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1200\/JCO.2017.35.15_suppl.9500","article-title":"A Phase III randomized study of adjuvant ipilimumab (3 or 10Mg\/Kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms","volume":"35","author":"Tarhini AA","year":"2017","unstructured":"Tarhini AA , Lee SJ , Hodi FS A Phase III randomized study of adjuvant ipilimumab (3 or 10Mg\/Kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms. Journal of Clinical Oncology. 35(Suppl. 15), 9500 (2017).","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"e_1_3_4_71_2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM198210073071503","article-title":"A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma","volume":"307","author":"Veronesi U","year":"1982","unstructured":"Veronesi U , Adamus J , Aubert C . A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N. Engl. J. Med. 307(15), 913\u2013916 (1982).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"e_1_3_4_72_2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber J","year":"2017","unstructured":"Weber J , Mandala M , Del Vecchio M Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377(19), 1824\u2013 1835 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_4_73_2","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma","author":"Mocellin S","year":"2017","unstructured":"Mocellin S , Lens MB , Pasquali S , Pilati P , Chiarion Sileni V . Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst. Rev. 6, CD008955 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_4_74_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline \u2013 update 2016","volume":"63","author":"Garbe C","year":"2016","unstructured":"Garbe C , Peris K , Hauschild A Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline \u2013 update 2016. Eur. J. Cancer 63, 201\u2013217 (2016).","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"e_1_3_4_75_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1529-8019.2005.00051.x","article-title":"Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease","volume":"19","author":"Lens M","year":"2006","unstructured":"Lens M . Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Derm. Ther. 19(1), 9\u201318 (2006).","journal-title":"Derm. Ther."},{"issue":"7","key":"e_1_3_4_76_2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","article-title":"Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma","volume":"106","author":"Verma S","year":"2006","unstructured":"Verma S , Quirt I , McCready D Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106(7), 1431\u20131442 (2006).","journal-title":"Cancer"},{"issue":"4","key":"e_1_3_4_77_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley K","year":"2003","unstructured":"Wheatley K , Ives N , Hancock B , Gore M , Eggermont A , Suciu S . Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev. 29(4), 241\u2013252 (2003).","journal-title":"Cancer Treat. Rev."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2019-0061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:40:13Z","timestamp":1679229613000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2019-0061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":76,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.2217\/cer-2019-0061"],"URL":"https:\/\/doi.org\/10.2217\/cer-2019-0061","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}